Stock Price, News, Quote and Profile of GERON CORP(NASDAQ:GERN) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

GERON CORP

NASDAQ:GERN (4/25/2024, 11:45:49 AM)

3.465

-0.12 (-3.21%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap2.03B

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 107 full-time employees. The firm is focused on the development and commercialization of imetelstat, a therapeutic for hematologic malignancies. The firm operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13mer oligonucleotide that the Company designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Its lead indication for imetelstat is in low or intermediate-1 risk myelodysplastic syndromes (MDS). The company is also engaged in the development of two indications, such as the treatment of adult patients with transfusion-dependent anemia due to lower risk MDS, and the treatment of adult patients with Intermediate-2 or High-Risk MF whose disease has relapsed after or is refractory to janus associate kinase inhibitor (JAK) inhibitor treatment.